Abstract
Alzheimers disease (AD) is a devastating neurodegenerative disease for which there are no highly effective therapies. A novel therapeutic approach to the treatment of AD is the use of agonists of the nuclear receptor, peroxisome proliferators-activated receptor gamma (PPARγ). PPARγ is a ligand activated transcription factor whose best described roles are to regulate lipid metabolism and inflammation. Agonists of PPARγ have been shown to ameliorate AD-related pathology in animal models of AD and improve cognition. A number of potential mechanisms have been advanced to account for these effects. PPARγ agonists act as insulin sensitizers, facilitating insulin action. In addition, PPARγ agonists have been shown to inhibit inflammatory gene expression, alter A β homeostasis and exhibit neuroprotective effects. Importantly, recent clinical trials of FDA approved PPARγ agonists have been shown to improve cognition and memory in AD patients. Thus, PPAR agonists represent a new and potentially efficacious treatment of AD.
Keywords: Alzheimer's Disease, peroxisome proliferator-activated receptor gamma, nuclear receptors, diabetes, insulin sensitizers, beta amyloid
Current Alzheimer Research
Title: Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Volume: 4 Issue: 2
Author(s): Gary Landreth
Affiliation:
Keywords: Alzheimer's Disease, peroxisome proliferator-activated receptor gamma, nuclear receptors, diabetes, insulin sensitizers, beta amyloid
Abstract: Alzheimers disease (AD) is a devastating neurodegenerative disease for which there are no highly effective therapies. A novel therapeutic approach to the treatment of AD is the use of agonists of the nuclear receptor, peroxisome proliferators-activated receptor gamma (PPARγ). PPARγ is a ligand activated transcription factor whose best described roles are to regulate lipid metabolism and inflammation. Agonists of PPARγ have been shown to ameliorate AD-related pathology in animal models of AD and improve cognition. A number of potential mechanisms have been advanced to account for these effects. PPARγ agonists act as insulin sensitizers, facilitating insulin action. In addition, PPARγ agonists have been shown to inhibit inflammatory gene expression, alter A β homeostasis and exhibit neuroprotective effects. Importantly, recent clinical trials of FDA approved PPARγ agonists have been shown to improve cognition and memory in AD patients. Thus, PPAR agonists represent a new and potentially efficacious treatment of AD.
Export Options
About this article
Cite this article as:
Landreth Gary, Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362092
DOI https://dx.doi.org/10.2174/156720507780362092 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthetic Peptides As Non-Viral DNA Vectors
Current Gene Therapy TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Reviews on Recent Clinical Trials Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry Hydroxamic Acids as Pharmacological Agents: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Chest Pain in Children
Current Pediatric Reviews <i>Larrea tridentata</i> and its Biological Activities
Current Topics in Medicinal Chemistry Therapeutic Targets in Extracellular Protein Deposition Diseases
Current Medicinal Chemistry Nanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences
Current Medicinal Chemistry Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
Current Cancer Drug Targets Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment
CNS & Neurological Disorders - Drug Targets Is There a Role for PDE5 Inhibitors in the Management of Male Infertility Due to Defects in Testicular or Epididymal Function?
Current Pharmaceutical Design Ultrasound Assisted Synthesis of 2-alkynyl Pyrazolo[1,5-a]pyrimidines as Potential Anti-cancer Agents
Letters in Drug Design & Discovery Mechanisms of HIV-1 Tat Neurotoxicity via CDK5 Translocation and Hyper-Activation: Role in HIV-Associated Neurocognitive Disorders
Current HIV Research Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Regulatory Role of Anesthetics on Heme Oxygenase-1
Current Drug Targets Nanofibre Based Smart Pharmaceutical Scaffolds for Wound Repair and Regenerations
Current Pharmaceutical Design The Role of Traditional Chinese Herbal Medicines and Bioactive Ingredients on Ion Channels: A Brief Review and Prospect
CNS & Neurological Disorders - Drug Targets 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design